Loading article
Medications
What bioequivalence means, why prices differ, when substitution is reasonable, and when brand consistency matters.
This article is for general information and does not constitute medical advice. Treatment decisions are made by an AHPRA-registered doctor after reviewing your circumstances.
Key information
Generic medicines can feel suspiciously cheap if you have never had bioequivalence explained. The cheaper price does not mean the active ingredient is weaker. It usually means the product entered the market after the original medicine's development costs and patent period.
The practical question is not whether brands are always better or generics are always identical. It is whether the available brands are substitutable for the medicine, dose form, person, and clinical situation.
The Therapeutic Goods Administration describes a generic prescription medicine as another brand of an existing medicine. It contains the same active ingredient, which is the chemical that makes the medicine work.
For a generic prescription medicine to be supplied in Australia, the TGA must be satisfied that it meets required standards for quality, safety, and efficacy. For many generic medicines, that includes evidence of bioequivalence to the original or reference medicine.
Generic medicines may use:
Those visible differences are why people often worry. The regulatory question is whether the active medicine reaches the body in a comparable way.
Bioequivalence compares how much of the active ingredient reaches the bloodstream and how quickly it gets there.
In a typical bioavailability study, volunteers receive the original medicine on one occasion and the generic medicine on another. Blood samples are taken over time, and the rate and extent of absorption are compared.
Plain English version:
Bioequivalence does not mean every tablet looks the same. It does not mean inactive ingredients are identical. It also does not mean a person will never notice a difference in taste, size, swallowing, packaging, or side effects from excipients.
For an approved generic equivalent, these should usually match the reference product:
| Feature | What it means |
|---|---|
| Active ingredient | The medicine molecule that produces the effect |
| Strength | The labelled dose, such as 20 mg or 500 mg |
| Intended route | Tablet, capsule, liquid, topical, injection, inhaled product, or another form |
| Therapeutic purpose | Same approved active ingredient use context |
| Quality standard | Must meet Australian regulatory requirements |
| Bioequivalence where required | Comparable absorption rate and extent |
This is why a generic blood pressure tablet, statin, antidepressant, reflux medicine, or antibiotic is often clinically reasonable when it is properly substitutable.
The differences are usually outside the active ingredient:
Bioequivalence
The packaging can differ, but approved generics must meet the active ingredient, quality, and bioequivalence standards that apply in Australia.
These differences can still matter for real-world use. A larger tablet may be harder to swallow. A different blister pack may confuse someone who uses a Webster-pak or dose administration aid. A dye, lactose, preservative, or flavouring may matter for a person with a specific intolerance.
Generic does not mean careless. It means equivalent in the active ingredient and regulatory sense, with practical differences that may still need attention.
In Australia, prescriptions for many PBS medicines use active ingredient prescribing. That means the prescription often lists the medicine by active ingredient rather than only by a brand name.
At the pharmacy, a pharmacist may offer a different brand when substitution is permitted and clinically appropriate. The prescriber can indicate that brand substitution is not permitted, and the patient can ask questions before accepting a change.
Brand substitution is usually reasonable when:
It is reasonable to ask the pharmacist: "Is this the same active ingredient and strength, and is there any reason I should stay with my current brand?"
The Pharmaceutical Benefits Scheme subsidises many medicines. In some cases, one brand may attract an extra brand premium if cheaper substitutable brands are available.
That means two products can contain the same active ingredient and strength, but one may cost more because of the brand chosen. The PBS subsidises up to the relevant base price; the patient may pay the premium if they choose a higher-priced brand.
Cost can also differ on private prescriptions, where PBS pricing does not control the final price in the same way.
Practical pharmacy questions:
Some medicines have a narrow therapeutic index, meaning small changes in blood concentration can affect benefit or toxicity. Others depend on device technique, release mechanism, or careful monitoring.
Extra caution is sensible with:
Substitution check
Active ingredient, strength, substitutability, prescriber instruction, excipients, and patient preference all matter at the pharmacy counter.
| Medicine or product type | Why consistency may matter |
|---|---|
| Warfarin | INR control can be sensitive to changes |
| Lithium | Blood levels are monitored and toxicity risk matters |
| Phenytoin and some anti-epileptic medicines | Small level changes may affect seizure control or side effects |
| Tacrolimus, ciclosporin, and transplant medicines | Blood levels and transplant stability matter |
| Levothyroxine | Thyroid levels may be monitored after changes |
| Modified-release products | Release design can be clinically important |
| Inhalers | Device technique can change the delivered dose |
| Patches | Adhesive, release rate, and skin tolerability can vary |
| Biologics and biosimilars | Similar concept, different regulatory and clinical conversation |
The point is not panic. The point is consistency. If a clinician, specialist clinic, or pharmacist has told you to stay with a specific brand, do not switch casually.
Some people report feeling different after switching brands even when products are bioequivalent.
Possible explanations include:
Do not dismiss symptoms automatically. Record what changed, the dates, the brand names, batch details if relevant, and the symptoms. Then ask the pharmacist or prescriber whether the switch should be reversed, monitored, or investigated.
Useful checks:
Consistency boundary
Narrow therapeutic index medicines, modified-release products, inhalers, patches, and biologics can make switching more complex.
This is especially important for older patients, people taking many medicines, people using dose administration aids, and anyone with allergy or intolerance history.
Generic medicines are not second-class medicines. In Australia, approved generics must meet TGA standards, and for many prescription medicines that includes bioequivalence evidence.
For most common medicines, choosing a generic is a reasonable way to reduce cost without reducing treatment quality. The exceptions are practical and clinical: narrow therapeutic index medicines, device-based medicines, modified-release products, biologics, excipient intolerance, and situations where a clinician has requested brand consistency.
Australian eScripts can be delivered as SMS or email tokens or managed through an Active Script List. Learn what the pharmacy sees, how repeats work, when paper still matters, and what to do if a token is lost.
Online prescriptions are legal and safe when issued by AHPRA-registered doctors following Australian prescribing standards. This guide covers the full process, from submitting your request to filling your eScript at any pharmacy.
Telehealth can prescribe most common medications for established patients. Schedule 8 controlled drugs, new medications requiring examination, and several other categories require in-person assessment. Here is the complete picture.